拉米夫定联合血浆置换治疗慢性乙型重型肝炎  

Effect of Lamivudine Combined with Plasmaexchange in Treatment of Chronic Fulminant Hapatitis B

作　　者：曹荣[1] 阮连国[1] 胡旭东[1] 程海林[1] 李宏杰[1] 徐德翠 黄少平[1] 

机构地区：[1]武汉市医疗救治中心,武汉430022

出　　处：《药物流行病学杂志》2009年第2期88-90,共3页Chinese Journal of Pharmacoepidemiology

摘　　要：目的:观察拉米夫定联合血浆置换治疗慢性乙型重型肝炎的疗效。方法:将48例慢性乙型重型肝炎患者随机分为对照组(22例),给予内科综合及血浆置换治疗;治疗组(26例),在此基础上加用拉米夫定,比较两组临床症状、TB(总胆红素)、PTA(凝血酶原活动度)、ALB及HBV-DNA含量。结果:治疗组在改善TB、PTA及提高治疗有效率、HBV-DNA阴转率方面较对照组差异有显著性(P<0.05)。结论:拉米夫定在血浆置换等的治疗基础上有可能进一步提高慢性乙型重型肝炎患者的治疗效果。Objective ： To study the effect of lamivudine combined with plasmaexchange in the treatment of chronic fulminant hapatitis B. Method： 48 patients with chronic fulminant hepatitis B were randomly divided into two groups. The therapy group was given lamivudine, based on plasmaexchange and other general treatment, while the controlled group was given the same treatment without lamivudine. And the main symptoms, TB, PTA, ALB and HBVDNA were observed and checked after treatment. Result： Significant differences were found between the two groups in the TB and PTA changes, HBVDNA loss and effective ratios. Conclusion： Lamivudine can improve the effects further bassed on the plasmaexchange treatment of chronic fulminant hepatitis B.

关 键 词：乙型肝炎/重型 慢性 拉米夫定 血浆置换 

分 类 号：R978.7[医药卫生—药品]